LY186126 was found to be a potent inhibitor of type IV cyclic AMP phosphodiesterase located in the sarcoplasmic reticulum of canine cardiac muscle. This compound, a close structural analogue of indolidan (LY195115), was prepared in high specific activity, tritiated form to study the positive inotropic receptor(s) for cardiotonic phosphodiesterase inhibitors such as indolidan and milrinone. A high-affinity binding site for [ 
I ndolidan (LY195115), a dihydropyridazinone cardiotonic (Figure 1 ), exhibits potent positive inotropic and vasodilator activities and is being tested clinically for treatment of congestive heart failure. 1 This compound was recently shown to be a potent, selective inhibitor of cyclic AMP (cAMP) phosphodiesterase (PDE) located in sarcoplasmic reticulum membranes (SR-PDE). 2 Based on high affinity for cAMP (/C m =0.46 /u,M) and lack of stimulation by calmodulin and cyclic GMP, SR-PDE is classified as a type IV PDE according to current nomenclature 3 and appears to be identical to cyclic GMP-inhibited PDE, or PDE HI, from cardiac muscle as described by others. 4 - 5 Potencies for in vivo stimulation of cardiac contractility by indolidan and a series of cardiotonic PDE inhibitors (e.g., milrinone, enoximone, and imazodan) were highly correlated with IC 50 values versus SR-PDE, suggesting that inhibition of SR-PDE is involved in the positive inotropic effects of these drugs. 2 The ability of these same agents to relax serotonincontracted, isolated vascular smooth muscle was also highly correlated with IC 50 values versus cardiac SR-PDE, 6 suggesting that a similar or identical PDE isozyme in the vasculature may be responsible for vasodilation. Thus, the pharmacological actions of indolidan appear to be explained by isozymeselective inhibition of PDE.
A close structural analogue of indolidan, LY186126, was prepared in a high specific activity, tritiated form ( Figure 1 ) to radiolabel the positive inotropic receptors) for this class of cardiotonics. These studies were designed to test further the hypothesis that inhibition of SR-PDE is the biochemical mechanism underlying direct cardiac effects of the dihydropyridazinones. The results demonstrate that [ 3 H]LY186126 binds specifically and with high affinity to a highly purified preparation of cardiac sarcoplasmic reticulum (SR) vesicles. Preliminary findings suggest a role for this site in mediating positive inotropic effects of these compounds.
Materials and Methods

Isolation of Canine Cardiac Membranes
Crude cardiac microsomes were prepared by standard techniques of differential centrifugation. Purpose-bred hounds (15-20 kg) were anesthetized with sodium pentobarbital (35 mg/kg i.v.), and their hearts were removed and placed in 154 mM NaCI (0-4° C). All subsequent operations were carried out at 0-4° C. Ventricular muscle was homogenized in 50 mM Tris-Cl, 5 mM MgCl 2 , pH 7.4 (1:10, wt/ vol) using a Polytron apparatus (Brinkmann Instruments, Westbury, New York) equipped with the PT20 generator. Following a low speed spin at 12,000# for 7 minutes, the supernatant fluid was centrifuged at 100,000# for 60 minutes. The resulting pellet was resuspended in the above buffer containing 0.01% bovine serum albumin (BSA) and was subsequently used in the binding assay. Purified SR vesicles (fraction E) were isolated from canine ventricles by the procedure described by Jones and Cala. 7 Vesicle protein was determined by the BCA protein assay 8 using bovine serum albumin (BSA; fraction V) as the protein standard. Membrane vesicles were stored frozen at -80° C in 0.25 M sucrose, 10 mM histidine, pH 7.5, for up to 2 months with no detectable changes in properties of the binding site described below.
Determination of Enzyme Activities
PDE activity of cardiac SR vesicles was determined at 1 fiM C A M P as described in a previous report.
2 Dimethyl sulfoxide was utilized as solvent for stock solutions of LY186126. Solutions of the inhibitor were prepared on the day of an experiment, and controls were run to ensure that carryover solvent (2.5%, vol/vol) had no effect on assay results. Inhibition curves were constructed by varying the concentration of inhibitor over a range of 2.5 log units encompassing the IC30 (concentration producing 50% inhibition of PDE activity). Ca 2+ -ATPase activity was quantitated at 37° C by appearance of inorganic phosphate as described previously. 7 
Determination of Membrane Binding
Binding studies were carried out at 25° C in 1.0 ml of the following medium: 50 mM Tris-Cl, 5 mM MgCl 2 , 0.01% BSA, pH 7.4, in the presence of varying concentrations of [ 3 H]LY186126. Dimethyl sulfoxide (DMSO) was employed as solvent for displacing ligands; control studies demonstrated that DMSO had no detectable effect on binding. Binding reactions were allowed to proceed to completion (60 minutes), at which time the membrane suspension was filtered using a vacuum apparatus (Brandel cell harvestor, Gaithersburg, Maryland) onto Whatman GF/C filters (Clifton, New Jersey) pretreated with 50 mM Tris-Cl, 0.05% BSA, pH 7.4, to minimize nonspecific binding. Filters were washed rapidly four times with cold (0-4° C) 50 mM sodium phosphate, pH 7.4. Total radioactivity retained by the filter was determined by scintillation counting filters in 10 ml Beckman Ready Protein + cocktail. Specific binding was defined as the portion of total bound radioactivity displaced by 100 ^.M indolidan. Binding was determined in triplicate at each concentration of [ 
Analysis of Data
ICJO values for inhibition of PDE activity were determined graphically from inhibition curves (percent activity versus negative logarithm of inhibitor concentration). 
Materials
The synthesis and characterization of [
tetrahydro-4-methyl-6-oxo-3-pyridazinyl)-2//-indol-2-one; 79.2 Ci/mmol) has been described. 9 The radiolabeled drug was highly stable and the radiochemical purity was 99.8% after 1 year of storage at -20° C in ethanol (data not shown). The synthesis and characterization of indolidan and LY186126 were as described in the literature 10 (indicated compounds were designated as numbers 20 and 26, respectively, in this reference). Milrinone was kindly supplied by SterlingWinthrop, New York, New York, and prazosin was a gift from Pfizer Laboratories, New York, New York. BCA protein reagent was obtained from Pierce Chemicals, Rockford, Illinois. BSA (fraction V), trypsin (bovine pancreatic), and propranolol were purchased from Sigma Chemical, St. Louis, Missouri. Nifedipine was obtained from Miofar, Milano, Italy. [ onstrated that BSA had no effect on specific binding to SR vesicles (data not shown). Furthermore, specific binding was abolished by the following: removal of Mg 24 from the binding medium, boiling the membranes for 1 minute, or subjecting membranes to proteolysis with trypsin (data not shown).
A representative binding isotherm depicting total, specific, and nonspecific binding is shown in Figure  2 . Despite the use of BSA in the binding medium, nonspecific binding was unacceptably high at [ 3 H]LY186126 concentrations greater than 80-100 nM; consequently, data in this range were unreliable and are not reported. Scatchard replots of the binding data were linear (Figure 2, inset 10 In the present report, LY186126 was found to be a potent inhibitor of SR-PDE. Based on the observed IQo of 0.12 fiM, LY186126 was equipotent to indolidan (IC^O.13 /uM) 2 as an inhibitor of SR-PDE. These findings, together with the chemical means for facile introduction of tritia into the indole methyl group, provided the rationale for selecting LY 186126 as the target compound for synthesis of a potential radioligand for the cardiotonic receptors) of indolidan.
A specific, high-affinity (K 6 =4 nM), saturable binding site for [
